Ravulizumab
How it works: Medicines for NMOSD and MOGAD →
Ultomiris
EU: Approved in the EU since 2019US: FDA approved 2018
- Molecule type
- Antibody
- Mechanism (ChEMBL)
- Complement C5 inhibitor
- Targets
- Complement C5
- Availability
- Authorised in all EU and EEA countries. Reimbursement is decided by each country.
Approvals
Safety communications
None recorded.
Most-reported side effects (FDA reports)
Reports to the FDA's adverse event system (FAERS) show what people and doctors reported while taking the medicine. They do not prove the medicine caused it, and they are not rates.
13,443 reports in total, 7,475 marked serious.
- Fatigue1,777
- Asthenia891
- Headache758
- Drug ineffective737
- Death590
- Off label use563
- Dyspnoea517
- Muscular weakness508
- Myasthenia gravis474
- Malaise467
Trials
Key trials
Large trials with a reported result on their main goal.
- Ravulizumab, phase 3
Completed · Phase 3 · NMOSD · Main goal met
Running now
- BEST-NMOSD
Recruiting · Phase 4 · NMOSD · ongoing
- Ravulizumab, phase 3
Recruiting · Phase 3 · NMOSD · ongoing
- Ravulizumab
Recruiting · NMOSD · ongoing
- AMAZE
Recruiting · NMOSD · ongoing
- Ravulizumab, phase 2 / phase 3
Running, not recruiting · Phase 2 / Phase 3 · NMOSD · ongoing
- Ravulizumab, phase 2 / phase 3
Running, not recruiting · Phase 2 / Phase 3 · NMOSD · ongoing
- Ravulizumab, phase 2 / phase 3
Ongoing · Phase 2 / Phase 3 · NMOSD
For information only, not medical advice. Talk to your neurologist before changing treatment.
Hypotheses involving this medicine
Loading hypotheses…
Loading reviews and guidelines…
Lab studies
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error